M
26.20
1.70 (6.94%)
| Previous Close | 24.50 |
| Open | 24.69 |
| Volume | 11,006,115 |
| Avg. Volume (3M) | 11,481,673 |
| Market Cap | 10,129,522,688 |
| Price / Sales | 4.20 |
| Price / Book | 1.24 |
| 52 Weeks Range | |
| Earnings Date | 1 May 2025 |
| Profit Margin | -110.04% |
| Operating Margin (TTM) | -128.99% |
| Diluted EPS (TTM) | -9.28 |
| Quarterly Revenue Growth (YOY) | -65.60% |
| Total Debt/Equity (MRQ) | 6.85% |
| Current Ratio (MRQ) | 3.67 |
| Operating Cash Flow (TTM) | -3.00 B |
| Levered Free Cash Flow (TTM) | -3.09 B |
| Return on Assets (TTM) | -15.14% |
| Return on Equity (TTM) | -28.77% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Moderna, Inc. | Bearish | Bearish |
AIStockmoo Score
-0.6
| Analyst Consensus | 1.0 |
| Insider Activity | -3.0 |
| Price Volatility | 0.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -2.5 |
| Average | -0.60 |
|
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Core |
| % Held by Insiders | 7.27% |
| % Held by Institutions | 72.80% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Theleme Partners Llp | 31 Dec 2024 | 7,306,861 |
| Flagship Pioneering Inc. | 31 Dec 2024 | 4,632,149 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 78.00 (UBS, 197.71%) | Buy |
| Median | 40.00 (52.67%) | |
| Low | 32.00 (Morgan Stanley, 22.14%) | Hold |
| Average | 44.78 (70.92%) | |
| Total | 1 Buy, 6 Hold, 2 Sell | |
| Avg. Price @ Call | 34.93 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 09 Apr 2025 | 32.00 (22.14%) | Hold | 26.67 |
| JP Morgan | 21 Mar 2025 | 33.00 (25.95%) | Sell | 32.66 |
| Citigroup | 13 Mar 2025 | 40.00 (52.67%) | Hold | 34.30 |
| UBS | 19 Feb 2025 | 78.00 (197.71%) | Buy | 35.90 |
| Barclays | 18 Feb 2025 | 45.00 (71.76%) | Hold | 35.75 |
| RBC Capital | 18 Feb 2025 | 40.00 (52.67%) | Hold | 35.75 |
| B of A Securities | 11 Feb 2025 | 34.00 (29.77%) | Sell | 30.93 |
| Goldman Sachs | 29 Jan 2025 | 51.00 (94.66%) | Hold | 40.72 |
| 28 Jan 2025 | 99.00 (277.86%) | Buy | 44.94 | |
| Evercore ISI Group | 27 Jan 2025 | 50.00 (90.84%) | Hold | 41.65 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| MOCK JAMES M | - | 25.11 | -703 | -17,652 |
| Aggregate Net Quantity | -703 | |||
| Aggregate Net Value ($) | -17,652 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 25.11 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MOCK JAMES M | Officer | 04 Apr 2025 | Disposed (-) | 703 | 25.11 | 17,652 |
| MOCK JAMES M | Officer | 04 Apr 2025 | Option execute | 1,452 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |